Day: August 10, 2022

Planned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) on trackISELIN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced its financial results for its fiscal third quarter ended June 30, 2022, provided recent corporate highlights, and reiterated its anticipated near-term milestones. Recent Corporate HighlightsAnnounced the full cash pre-payment of its $12.3 million unsecured convertible promissory note dated November 4, 2020, as amended November 16, 2021; and Confirmed plans to re-submit ONS-5010 BLA by September 2022.“We...

Sales of $31.9 million for the quarter, an increase of 21% over Q2 2021 Sales of $62.9 million for the six-month period, an increase of 25% over 2021 Completed the acquisition of Knitting Machinery Company of AmericaCLEVELAND, Aug. 10, 2022 (GLOBE NEWSWIRE) — Crawford United Corporation (OTC: CRAWA), a growth-oriented holding company serving diverse markets, today reported results for the three-month and six-month periods ended June 30, 2022. For the quarter ended June 30, 2022, sales were $31.9 million compared to $26.4 million in the same period last year, an increase of 21%. In this quarter, the Company recorded operating income of $2.4 million compared to $2.1 million in the same period last year, an increase of 12%. Net income was $1.2 million, or $0.34 per fully diluted share, compared to $1.2 million, or $0.37 per fully...

Revenue Growth of 14% Year-over-Year in Q2 2022 Conference call to be held today, August 10, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 10, 2022 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported second quarter 2022 financial results and provided an operational update. Recent Financial and Operational HighlightsFor the three months ended June 30, 2022, revenues were $8.0 million, a 14% increase as compared to the prior year period. As of June 30, 2022, BrainsWay’s Deep TMS™ installed base was 829 total systems, a 22% increase from the installed base at the same point in the prior year. As of June 30, 2022, the Company had shipped 368 obsessive-compulsive disorder (OCD) coils as add-on...

Completed enrollment for Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy; topline data now expected to be presented in early Q1 2023 Presented positive 12-week interim analysis of Phase 2 study of MAU868 in kidney transplant recipients with BK Virus viremia at American Transplant Congress in June 2022; expect to initiate a Phase 2b or Phase 3 clinical trial in 2023 Strong balance sheet with approximately $131.9 million in cash, cash equivalents, and marketable securities as of June 30, 2022 and access to a $45.0 million credit facility expected to fund operations to Q2 2024BRISBANE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases,...

Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard’s Dana Farber Cancer Institute, Brigham & Women’s Hospital, and Medical University of Lodz for development of a diagnostic test for endometriosis Reduced cash utilization by $3.9 Million in the Second Quarter 2022 Conference Call and Webcast scheduled for today, August 10th at 8:30 a.m. ET AUSTIN, Texas, Aug. 10, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2022. “We are pleased by our continued progress and execution during the second quarter, particularly on our three key strategic initiatives: Growth,...

Figure 1 Development MapCALGARY, Alberta, Aug. 10, 2022 (GLOBE NEWSWIRE) — (PIPE – TSX) Pipestone Energy Corp. (“Pipestone” or the “Company”) is pleased to report its second quarter 2022 financial and operational results, and to provide an update on its operations. SECOND QUARTER 2022 CORPORATE HIGHLIGHTS:The Company generated record revenue of $210.4 million, which represents more than a two and a half times increase over Q2 2021 revenue of $82.3 million, and a 37% increase from Q1 2022 revenue of $153.5 million; In Q2 2022, Pipestone achieved record average quarterly production totaling 30,770 boe/d (28% condensate, 41% total liquids), representing a 32% quarterly increase over Q2 2021 production of 23,336 boe/d (31% condensate, 46% total liquids), and a 12% increase over Q1 2022 production of 27,581 boe/d (29% condensate,...

Marketplace growth accelerates: Revenue increases 89% year-over-year driven by accelerating marketplace growth as well as supplier services including Thomas. Strong gross margin and gross profit trends driven by AI pricing/supplier selection and additional supplier services: Gross profit up 217% year-over-year. Marketplace gross profit increased 25% quarter-over-quarter. Expect strong growth for balance of 2022: We expect revenue growth of 81-83% to $395-$400 million, driven by increasing active buyers and suppliers, added supplier services and revenue synergies with Thomas. Expect further operating leverage: Q2 Adjusted EBITDA loss of $8.3 million, a $4.4 million quarter-over-quarter improvement. We expect operating leverage to further improve in the second half of 2022. We expect to be Adjusted EBITDA positive for 2023. Robust marketplace...

Second quarter revenues of $58.1 million, net of non-cash warrants impact of $4.5 million, in line with preliminary results issued on July 5, 2022 Second quarter GAAP operating loss of $24.9 million; Non-GAAP operating loss of $18.3 million, net of $4.5 million attributed to the non-cash impact of warrants Board of Directors approves $75 million share repurchase program Announces CFO transition; Industry veteran Lauri Hanover to join Kornit executive management team as Chief Financial OfficerROSH-HA`AYIN, Israel, Aug. 10, 2022 (GLOBE NEWSWIRE) — Kornit Digital Ltd. (“Kornit” or “the Company”) (Nasdaq: KRNT), a worldwide market leader in sustainable, on-demand, digital fashionX and textile production technologies, reported today results for the second quarter ended June 30, 2022. “While the overall operating environment remains...

– Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – – Oncology pipeline advancing with novel LockBody® technology – – Announces discontinuation of ZF874 for AATD – – Multiple clinical PoC readouts expected across pipeline over next two years – – Cash and cash equivalents of $484.2 million as of June 30, 2022; Cash runway into 2026 – BOSTON and LONDON, Aug. 10, 2022 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, today reported financial results and business highlights for the second quarter ended June 30, 2022, and provided a program update for ZF874 for...

NEW YORK, Aug. 10, 2022 (GLOBE NEWSWIRE) — 1stdibs.com, Inc. (NASDAQ: DIBS), a leading online marketplace for luxury design products (“1stDibs” or the “Company”), today reported financial results for its second quarter ended June 30, 2022. Second Quarter 2022 Financial HighlightsNet revenue was $24.6 million, a decrease of 0.5% year-over-year. Gross profit was $16.6 million, a decrease of 4% year-over-year. Gross margin was 67.6%, compared to 70.4% in the second quarter 2021. GAAP net loss was $0.3 million and included a $9.7 million gain on the Sale of Design Manager, compared to a net loss of $4.1 million in the second quarter 2021. Non-GAAP Adjusted EBITDA and Adjusted EBITDA Margin was $(6.1) million and (24.7)%, respectively, compared to $(3.0) million and (12.3)%, respectively, in the second quarter...